SS/Jr |
logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50) |
Kreb's solution perfusate then phenylephrine (1-100 mmol/l) |
Dutil J, et al., Physiol Genomics 2005 Mar 1;. |
vasoconstriction trait |
male |
98 days
| 12 |
-7.26 |
null |
0.06 |
0.21 |
tissue force analysis utilizing a force transducer |
0.0 |
0 |
isometric force transducer |
EC50 value is probably moles/liter |
69054 |
1096 |
SS/Jr |
receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio |
Kreb's solution perfusate then phenylephrine (1-100 mmol/l) |
Dutil J, et al., Physiol Genomics 2005 Mar 1;. |
vasoconstriction trait |
male |
98 days
| 12 |
104.06 |
% |
4.7 |
16.28 |
tissue force analysis utilizing a force transducer |
0.0 |
0 |
isometric force transducer |
|
69052 |
1096 |
SS/Jr |
logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50) |
Kreb's solution perfusate then phenylephrine (1-100 mmol/l) and NG-nitroarginine methyl ester (100 umol/l) |
Dutil J, et al., Physiol Genomics 2005 Mar 1;. |
vasoconstriction trait |
male |
98 days
| 12 |
-7.6 |
null |
0.05 |
0.17 |
tissue force analysis utilizing a force transducer |
0.0 |
0 |
isometric force transducer |
EC50 value is probably moles/liter |
69058 |
1096 |
SS.MNS-(D2Mit6-D2Rat303)/Ayd |
receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio |
Kreb's solution perfusate then phenylephrine (1-100 mmol/l) |
Dutil J, et al., Physiol Genomics 2005 Mar 1;. |
vasoconstriction trait |
male |
98 days
| 13 |
100.16 |
% |
5.63 |
20.3 |
tissue force analysis utilizing a force transducer |
0.0 |
0 |
isometric force transducer |
|
69053 |
1096 |
SS.MNS-(D2Mit6-D2Rat303)/Ayd |
receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio |
Kreb's solution perfusate then phenylephrine (1-100 mmol/l) and NG-nitroarginine methyl ester (100 umol/l) |
Dutil J, et al., Physiol Genomics 2005 Mar 1;. |
vasoconstriction trait |
male |
98 days
| 13 |
143.03 |
% |
6.62 |
23.87 |
tissue force analysis utilizing a force transducer |
0.0 |
0 |
isometric force transducer |
|
69057 |
1096 |
SS.MNS-(D2Mit6-D2Rat303)/Ayd |
logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50) |
Kreb's solution perfusate then phenylephrine (1-100 mmol/l) and NG-nitroarginine methyl ester (100 umol/l) |
Dutil J, et al., Physiol Genomics 2005 Mar 1;. |
vasoconstriction trait |
male |
98 days
| 13 |
-7.41 |
null |
0.16 |
0.58 |
tissue force analysis utilizing a force transducer |
0.0 |
0 |
isometric force transducer |
EC50 value is probably moles/liter |
69059 |
1096 |
SS.MNS-(D2Mit6-D2Rat303)/Ayd |
logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50) |
Kreb's solution perfusate then phenylephrine (1-100 mmol/l) |
Dutil J, et al., Physiol Genomics 2005 Mar 1;. |
vasoconstriction trait |
male |
98 days
| 13 |
-6.96 |
null |
0.17 |
0.61 |
tissue force analysis utilizing a force transducer |
0.0 |
0 |
isometric force transducer |
EC50 value is probably moles/liter |
69055 |
1096 |
SS/Jr |
receptor-dependent blood vessel maximum contractile force to receptor-independent blood vessel maximum contractile force ratio |
Kreb's solution perfusate then phenylephrine (1-100 mmol/l) and NG-nitroarginine methyl ester (100 umol/l) |
Dutil J, et al., Physiol Genomics 2005 Mar 1;. |
vasoconstriction trait |
male |
98 days
| 12 |
141.72 |
% |
7.73 |
26.78 |
tissue force analysis utilizing a force transducer |
0.0 |
0 |
isometric force transducer |
|
69056 |
1096 |